[{"address1": "5980 Horton Street", "address2": "Suite 550", "city": "Emeryville", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 925 2492", "website": "https://kyvernatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.", "fullTimeEmployees": 129, "companyOfficers": [{"maxAge": 1, "name": "Ms. Christi L. Shaw", "age": 57, "title": "Executive Chairperson", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 15840, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Warner  Biddle", "age": 58, "title": "CEO & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 1232292, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Walker", "age": 63, "title": "Chief Technology Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 591360, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Grasso M.D.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tom  Van Blarcom Ph.D.", "title": "Senior VP & Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Serra", "title": "Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cara  Bauer Ph.D.", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy  Rossin", "age": 49, "title": "Senior Vice President of Corporate Affairs & Communications and Investor Relations", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Maziasz", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Naji H. Gehchan M.B.A., M.D.", "age": 43, "title": "Chief Medical & Development Officer", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.21, "open": 8.24, "dayLow": 7.665, "dayHigh": 8.28, "regularMarketPreviousClose": 8.21, "regularMarketOpen": 8.24, "regularMarketDayLow": 7.665, "regularMarketDayHigh": 8.28, "payoutRatio": 0.0, "forwardPE": -2.351049, "volume": 1218988, "regularMarketVolume": 1218988, "averageVolume": 1486573, "averageVolume10days": 997190, "averageDailyVolume10Day": 997190, "bid": 5.91, "ask": 9.84, "bidSize": 2, "askSize": 2, "marketCap": 477448896, "fiftyTwoWeekLow": 1.78, "fiftyTwoWeekHigh": 13.67, "allTimeHigh": 30.6, "allTimeLow": 1.78, "fiftyDayAverage": 8.384, "twoHundredDayAverage": 5.196575, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 184693328, "profitMargins": 0.0, "floatShares": 25369369, "sharesOutstanding": 59606603, "sharesShort": 3408408, "sharesShortPriorMonth": 3489945, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0572, "heldPercentInsiders": 0.09106, "heldPercentInstitutions": 0.54793, "shortRatio": 1.18, "shortPercentOfFloat": 0.08270001, "impliedSharesOutstanding": 59606603, "bookValue": 3.47, "priceToBook": 2.3083575, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -160992000, "trailingEps": -3.64, "forwardEps": -3.40699, "enterpriseToEbitda": -1.084, "52WeekChange": 1.5838709, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 8.01, "targetHighPrice": 33.0, "targetLowPrice": 20.0, "targetMeanPrice": 29.6, "targetMedianPrice": 32.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 171138000, "totalCashPerShare": 3.908, "ebitda": -170456992, "totalDebt": 5024000, "quickRatio": 5.053, "currentRatio": 5.164, "debtToEquity": 3.306, "returnOnAssets": -0.40749002, "returnOnEquity": -0.70819, "grossProfits": -137188992, "freeCashflow": -95628248, "operatingCashflow": -157246000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "KYTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1769819270, "regularMarketTime": 1769806802, "shortName": "Kyverna Therapeutics, Inc.", "longName": "Kyverna Therapeutics, Inc.", "exchange": "NMS", "messageBoardId": "finmb_650816865", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -2.4360514, "regularMarketPrice": 8.01, "marketState": "CLOSED", "priceEpsCurrentYear": -2.1616516, "fiftyDayAverageChange": -0.3739996, "fiftyDayAverageChangePercent": -0.04460873, "twoHundredDayAverageChange": 2.813425, "twoHundredDayAverageChangePercent": 0.54139984, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-02-08", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1707489000000, "postMarketChangePercent": -0.37453446, "postMarketPrice": 7.98, "postMarketChange": -0.03000021, "regularMarketChange": -0.19999981, "regularMarketDayRange": "7.665 - 8.28", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1486573, "fiftyTwoWeekLowChange": 6.2300005, "fiftyTwoWeekLowChangePercent": 3.5000002, "fiftyTwoWeekRange": "1.78 - 13.67", "fiftyTwoWeekHighChange": -5.66, "fiftyTwoWeekHighChangePercent": -0.41404533, "fiftyTwoWeekChangePercent": 158.38708, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.64, "epsForward": -3.40699, "epsCurrentYear": -3.7055, "displayName": "Kyverna Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]